Funding Opportunity: NCATS Announces Awards to Test Pharmaceutical Industry Assets for New Therapies

For every drug that is approved by the U.S. Food and Drug Administration, many others are not due to lack of effectiveness in treating the disease they were designed to target. NCATS leads initiatives to repurpose some of these partially developed investigational drugs (also known as assets) to treat new disease indications and get more treatments to more patients more quickly.

Through its Discovering New Therapeutic Uses for Existing Molecules program, NCATS recently awarded nearly $3 million to support four academic research groups that will test a selection of pharmaceutical industry assets for new therapeutic uses. The awarded projects are aimed at finding therapies for:

  • Type 2 diabetes
  • Glioblastoma (one of the most aggressive brain tumors in adults)
  • Acute myeloid leukemia (an aggressive blood cancer)
  • Chagas disease (a neglected tropical disease that causes heart, digestive and neurological problems)

Each award recipient will test a selected asset for its effectiveness against a previously unexplored disease or condition. The industry partners for these projects are AstraZeneca and Sanofi.

Click the links below for more information: